688553 Sichuan Huiyu Pharmaceutical
- 10.07
- -0.06-0.59%
Sichuan Huiyu Pharmaceutical News
Huayu Pharmaceuticals (688553.SH): Methotrexate Injection has obtained a pharmaceutical registration certificate.
On September 18, Guanglonghui reported that Huayu Pharmaceutical (688553.SH) announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. Methotrexate can inhibit dihydrofolate reductase. Dihydrofolate must be reduced to tetrahydrofolate by this enzyme before it can be used as a carrier of one-carbon groups in the synthesis of purine nucleotides and thymidine monophosphate. Therefore, methotrexate interferes with DNA synthesis, repair, and cell replication. Proliferating tissues such as malignant tumor cells, bone marrow, embryonic cells, oral and intestinal mucosa, and bladder cells are usually more sensitive to the effects of methotrexate. Methotrexate has a wide
Yang Bo, a shareholder of Huiyu Pharmaceuticals (688553.SH), has completed the shareholding period and reduced a total of 0.0301 million shares.
Huayu Pharmaceutical (688553.SH) announced that the shareholder Yang Bo has gradually reduced his shareholding in the company through centralized auction trading...
Huiyu Pharmaceutical Gets Nod to Market Sodium Valproate Injection Concentrated Solution in Ireland
Sichuan Huiyu Pharmaceutical's (SHSE:688553) Shareholders May Want To Dig Deeper Than Statutory Profit
Huayu Pharmaceuticals (688553.SH): Plerixafor injection, Azacitidine for injection, and Setipiprant for injection have been granted market approval in Israel, Egypt, and Northern Ireland, respectively.
Gelonghui August 27th 丨 Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary Seacross Pharmaceuticals Ltd. recently received market approval for the company's products Pulisafu Injection, Azacitidine for Injection, and Cetuximab for Injection issued by the Israeli Ministry of Health, Egyptian Drug Authority, and the United Kingdom Medicines and Healthcare Products Regulatory Agency respectively.
Huiyu Pharmaceutical's Unit Gets Nod to Trial Tumor Drug
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Huayu Pharmaceutical (688553.SH): The net income in the first half of the year was 65.2134 million yuan, a year-on-year decrease of 5.08%.
On August 26th, Gelonghui announced its semi-annual report for the year 2024. During the reporting period, the company achieved revenue of 0.532 billion yuan, a year-on-year increase of 18.12%. The net income attributable to the shareholders of the listed company was 65.2134 million yuan, a year-on-year decrease of 5.08%. The net income attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 43.0925 million yuan, a year-on-year increase of 45.04%. The basic earnings per share was 0.15 yuan. The main reason for the year-on-year increase in net income attributable to shareholders of the listed company, after deducting non-recurring gains and losses, is the government subsidies received in this period compared to the same period last year.
Sichuan Huiyu Pharmaceutical Gets Nod to Market Osteoporosis Drug in Netherlands
Huiyu Pharmaceutical (688553.SH): Zolendronic acid injection received Dutch market approval.
On August 12th, Globio reports that Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, SeacrossPharma (Europe) Ltd., recently received approval from the Dutch Health Products Regulatory Agency to market its product, Zoledronic acid injection. Zoledronic acid injection is mainly used for the treatment of osteoporosis in postmenopausal women and adult men, osteoporosis induced by long-term glucocorticoid treatment in postmenopausal women and adult men, and Paget's disease of bone in adults.
Huiyu Pharmaceutical (688553.SH): Azacitidine for injection and bendamustine hydrochloride for injection obtained marketing approval in Uzbekistan
On August 7th, Gelunhui reported that Seacross Pharmaceuticals Ltd., a wholly-owned subsidiary of Huiyu Pharmaceutical (688553.SH), recently received approval and issuance of the license for the injection of Azacitidine and injection of Benidipine Hydrochloride for the company's product from the Uzbekistan Pharmaceutical Authority. Azacitidine injection is a cytidine nucleoside analogue that exerts an antitumor effect by causing DNA demethylation and direct cytotoxic effects on aberrant hematopoietic cells in the bone marrow. The injection of benidipine hydrochloride is used for chronic lymphocytic leukemia in patients who are not suitable for fludarabine-based combined chemotherapy.
Huiyu Pharmaceutical Gets Nod to Market Two Cancer Drugs
Huayu Pharmaceutical (688553.SH): Injection of Calcium Levofolinate and Methotrexate Injection received the pharmaceutical registration certificate.
On August 6th, Gelonghui reported that Huiyu Pharmaceutical (688553.SH) announced that the company received the "Drug Registration Certificate" issued and approved by the National Medical Products Administration. Calcium folinate enhances the efficacy and toxic effects of fluorouracil (such as 5-fluorouracil) in tumor treatment. 5-Fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-phosphate (FdUMP), which combines and inhibits thymidylate synthase (an enzyme that is very important in DNA repair and replication). In the body, calcium folinate can easily be converted to another reduced folate, 5,10-methylenetetrahydrofolate, which can stabilize deamination.
Huiyu Pharmaceutical Unit's Two Drugs Gets Nod to Be Marketed in Costa Rica, Ireland
Huiyu Pharmaceutical (688553.SH): Oxaliplatin Injection and Zoledronic Acid Injection have been granted market approval in Costa Rica and Ireland respectively.
On August 5th, Gelonhui reported that Huizhou Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Seacross Pharmaceuticals Ltd., recently received approval and issuance of product registration certificates for the company's products, Oxaliplatin Injection and Zoledronic Acid Injection, from the Ministry of Health of the Republic of Costa Rica and the Health Products Regulatory Authority of Ireland, respectively. Oxaliplatin Injection combined with 5-fluorouracil (5-FU) and folinic acid (FA) can be used to treat adjuvant chemotherapy for stage III colon cancer after complete resection of primary tumors and metastatic colon cancer. Zoledronic Acid Injection is mainly used.
Huiyu Pharmaceutical (688553.SH): Injection voriconazole and sodium propionic acid injection have been granted market approval in Portugal and Germany, respectively.
On August 1st, Gelonhui reported that the company's wholly-owned subsidiary, Seacross Pharma (Europe) Ltd., recently received market approvals for injection use of voriconazole and sodium valproate injection concentrated solution from the National Drug and Health Products Administration in Portugal and the Federal Drug and Medical Institutions in Germany.
Huiyu Pharmaceutical's Thiotepa for Injection Enters Portuguese Market
Huiyu Pharmaceuticals (688553.SH): Injection Setiparib obtains Portuguese license for listing.
On July 29th, Gelunhui reported that Huiyu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Seacross Pharma (Europe) Ltd., recently received approval for the marketing license of its company product, Setiparib, for injection, issued by the Portuguese National Drug and Health Product Administration. Setiparib for injection, in combination with other chemotherapy drugs, is suitable for adult and pediatric patients undergoing allogeneic or autologous hematopoietic progenitor cell transplantation (HPCT) before, during or after total body irradiation (TBI). When high-dose chemotherapy supported by HPCT is appropriate, it can be used to treat adults and children.
Huayu Pharmaceutical (688553.SH): Injection of Voriconazole and Zoledronic Acid Injection were granted market approval in Ireland and Portugal respectively.
On July 24th, Gelunhui reported that Huiyu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Seacross Pharma (Europe) Ltd., has recently received approval from the Irish Health Products Regulatory Authority and the National Drug and Health Product Administration of Portugal for the injection of fluconazole and zoledronic acid injection by the company. The injection of fluconazole is a broad-spectrum triazole antifungal drug mainly used to treat invasive aspergillosis; serious invasive infections caused by fluconazole-resistant Candida (including C. glabrata); infections caused by Fusarium
Analysis
Price Target
No Data
No Data